cytotoxic t-lymphocytes
Phase 2Small molecule
cytotoxic t-lymphocytes is one of 6 small molecule programs targeting Adenovirus Infection. It is currently in Phase 2.
2
Indications
4
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
5 competitors in EBV Infection
#DrugCompanyPhaseTrials
1Zuberitamab
BBioRay Pharmaceutical Co., Ltd.
Phase 2
Taxol
TevaPreclinical
cytotoxic t-lymphocytes
NNew York Medical College
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Adrucil
EElorac, Inc.
Preclinical
Gemzar
GGynecologic Oncology Group
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
COVID-191 trial
Adenovirus Infection1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for cytotoxic t-lymphocytes. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNew York Medical College